TRVN

Trevena Inc

TRVN.US trevena.com
Healthcare · Biotechnology
0.00
+0.00 (+0.00%)
USD · NASDAQ
52-week range
0.00
0.25
Trading at 0% of the 52-week range
Market Cap
9.50K
P/E Ratio
0.00
Forward P/E
0.00
Book Value
-27.27
Div. Yield
N/A
% Institutions
11.08%
% Insiders
0.484%

1 Year

-99.6%

3 Year

-100.0%

10 Year

-100.0%
Description

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Company Information

▼
Company Name
Trevena Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US89532E1091
CIK: 0001429560
CUSIP: 89532E109
Currency: USD
Full Time Employees: 23
Phone: 610 354 8840
Website: trevena.com
Fiscal Year End: December
IPO Date: Jan 31, 2014
Description:

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Address:

955 Chesterbrook Boulevard, Chesterbrook, PA, United States, 19087

People

▼

Directors & Officers

Name Title Year Born
Ms. Carrie L. Bourdow President, CEO & Chairman 1963
Dr. Mark A. Demitrack M.D. Senior VP & Chief Medical Officer 1958
Dr. Howard A. Rockman M.D. Scientific Founder, Consultant and Member of Scientific Advisory Board NA
Ms. Katrine Sutton Principal Financial Officer & principal accounting officer 1977
Mr. Robert T. Yoder Senior VP, Chief Business Officer, Head of Commercial Operations & Chief Compliance Officer 1966
Mr. Michael Catalano Vice President of Marketing NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jun 28, 2022 Barry Shin N/A Sale 50.00 $256.25 $12.81K

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Advisor Group Holdings, Inc. 0.00 Mar 31, 2025 0.00% $0.00 -100.00%
Activest Wealth Management 0.00 Mar 31, 2025 0.00% $0.00 -100.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity OTC 706.00 0.08% ▲ 0.00% Jul 31, 2026
2 Fidelity OTC Commingled Pool Class D 113.00 0.01% ▲ 0.00% Jul 31, 2026
3 Fidelity OTC K6 52.00 0.01% ▲ 0.00% Jul 31, 2026

Financial Highlights

▼
Market Cap: $9.50K
EBITDA: $-31.75M
PEG Ratio: $0.00
Book Value: $-27.27
Earnings/Share: $-48.89
Profit Margin: 0.00%
Operating Margin: -1,970.67%
ROA (TTM): -62.39%
ROE (TTM): -1,014.58%
Revenue (TTM): $546.00K
Revenue/Share (TTM): $0.69
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 57.20%

Valuation Metrics

Enterprise Value: $24.10M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 863.79K
Shares Float: 859.07K
% Insiders: 0.484%
% Institutions: 11.08%
Short % Float: 7.03%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

▼

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$3.13M
Cost of Goods Sold
adjust
$-1.67M
Gross Profit
subtotal
$1.46M
SG&A
adjust
$-21.52M
R&D
adjust
$-16.33M
Operating Income
subtotal
$-35.29M
Other / Non-Operating Items
adjust
$-5.00M
Net Income
subtotal
$-40.29M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about TRVN.US!